Melanoma News and Research

Latest Melanoma News and Research

Immunotherapy accepted for coverage in MEDLINE®

Future Medicine Ltd announced today that its journal Immunotherapy (ISSN 1750-743X) has been selected for coverage in MEDLINE®. Maintained by the U.S. National Library of Medicine, MEDLINE® (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in life sciences.

19 Sep 2010

Melanoma Foundation of New England to host fundraising gala to educate public on cancer

On Tuesday, October 26, 2010, the Melanoma Foundation of New England will be hosting Shades of Hope - a fundraising gala to be held at the InterContinental Boston Hotel. The Foundation's signature event, Shades of Hope is dedicated to those who inspire the foundation to educate the public on one of the deadliest forms of cancer.

15 Sep 2010

Study reveals men less likely to use active sun-protective measures

There is a significant disparity between knowledge and attitudes on the dangers of skin cancer among male and female medical students in Florida according to a new study by a joint team of researchers from Ben-Gurion University of the Negev and the University of Miami Miller School of Medicine. The study was published in the American Medical Association's Archives of Dermatology.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

Neoprobe Corporation presents information on Lymphoseek at TERACHEM Symposium

Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development, Dr. Frederick O. Cope, presented information on the Company's lead pipeline initiative, Lymphoseek, at the International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM), held September 8-11, 2010 in Bressanone (Bolzano), Italy.

14 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Sun tanning still in demand for Victorian teenagers: Survey

According to the latest survey Victorian teenagers, despite skin cancer warnings, are still keen on getting a sun tan. The online survey by SunSmart showed that young Victorians are significantly more sun-safe than they were when the Slip! Slop! Slap! campaign first started 30 years ago.

12 Sep 2010

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.

10 Sep 2010

Researchers to develop image analysis techniques for melanoma classification

Melanoma, the most serious form of skin cancer varies in size, shape and severity, and although pathologists and researchers often intuitively differentiate between types of melanomas, the variations have never been formally quantified and documented. A project involving RENCI and researchers in the University of North Carolina School of Medicine and the departments of computer science and statistics and operations research aims to change that by using image analysis techniques to improve melanoma classification.

10 Sep 2010

New melanoma drug in the pipeline from Plexxikon and Roche

Researchers from biotech company Plexxikon have found that their candidate drug for skin cancer melanomas can be administered more effectively in early stages of the disease.

9 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Overweight and obesity contribute to increase in womb cancer cases

The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

9 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Bristol-Myers Squibb Company and ZymoGenetics, Inc. announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.

8 Sep 2010

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of a European patent protecting its product acyclovir Lauriad.

8 Sep 2010

Melanoma News and Research

Latest Melanoma News and Research

Immunotherapy accepted for coverage in MEDLINE®

Melanoma Foundation of New England to host fundraising gala to educate public on cancer

Study reveals men less likely to use active sun-protective measures

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Neoprobe Corporation presents information on Lymphoseek at TERACHEM Symposium

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Sun tanning still in demand for Victorian teenagers: Survey

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers to develop image analysis techniques for melanoma classification

New melanoma drug in the pipeline from Plexxikon and Roche

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Overweight and obesity contribute to increase in womb cancer cases

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in